Mar 27, 2000|
NPIL–Reckitt JV under strain
Reckitt Benckiser, the $ 3.1 bn parent of Reckitt & Colman (R & C) India is reviewing the company’s joint venture (JV) with Nicholas Piramal (NPIL).
R & C India had transferred two of its over the counter pharmaceutical brands Dettol and Dispirin to the joint venture in which it held 20% while 40% each was held by its parent and NPIL respectively.
The transfer of the brands had hit the valuation of the listed company since the transfers were made without any consideration apart from giving R & C a 20% stake in the JV. Besides, it was also announced at the time of setting up of the venture that henceforth the pharmaceutical products of the parent would be introduced through the JV and not through R & C India.
The joint venture had a turnover of Rs 2.12 bn in the first nine months of FY 2000, a 9% growth over the previous year. This in fact is slightly over the overall formulations growth of 7% shown by the pharmaceutical industry. Companies such as Glaxo India that have a very high percentage of prescription brands have also grown by 9%. It is quite possible that had the brand remained with the listed company it would have grown equally if not more.
However, the impact of the reported review on the stocks of both R & C and NPIL is still not clear since an announcement on the future of the brands is still awaited. If the joint venture splits and the brands return to the R & C fold it would be a definite positive for the stock. (R & C ‘s parent had earlier requested the FIPB for setting up a 100% subsidiary which was rejected.)
NPIL has built a network of relationships with more than half a dozen alliances and joint ventures currently in operation. The importance of continuity in these relationships cannot be overstated. If for whatsoever reason relationships turn sour, it could damage NPIL’s value in the future.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407